Ocrelizumab Shows Hand Function Benefits in Advanced Progressive MS

(MedPage Today) — Ocrelizumab (Ocrevus) delayed overall disability progression and worsening of upper limb function in people with primary progressive multiple sclerosis (PPMS) over 144 weeks, the ORATORIO-HAND (O’HAND) trial showed.
In a large…